High-Dose N-Acetylcysteine in the Prevention of COPD Exacerbations: Rationale and Design of the PANTHEON Study

References

• Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/.
   Google Scholar
• Poole PJ, Black PN. Preventing exacerbations of chronic bronchitis and COPD: therapeutic potential of mucolytic agents. Am J Respir Med 2003; 2(5):367–370.
   PubMedGoogle Scholar
• Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5):1530–1535.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48(12):1204–1213.
   PubMedGoogle Scholar
• Zheng J-P, Kang J, Huang S-G, Chen P, Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): A randomized placebo-controlled study. Lancet 2008; 371:2013–2018.
   PubMed Web of Science ®Google Scholar
• Blackwell TS, Blackwell TR, Holden EP, Christman BW, Christman JW. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol 1996; 157(4):1630–1637.
   PubMed Web of Science ®Google Scholar
• Lappas M, Permezel M, Rice GE. N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro. J Clin Endocrinol Metab 2003; 88(4):1723–1729.
   PubMed Web of Science ®Google Scholar
• van Overveld FJ, Demkow U, Górecka D, de Backer WA, Zielinski J. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine. J Physiol Pharmacol 2005; 56 Suppl 4:135–142.
   PubMedGoogle Scholar
• Ekberg-Jansson A, Larson M, MacNee W, Tunek A, Wahlgren L, Wouters EF, Larsson S. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur Respir J 1999; 13:829–834.
   PubMed Web of Science ®Google Scholar
• Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: Discordant in vitro and in vivo dose-effects: A review. Pulm Pharmacol Ther 2007; 20:9–22.
   PubMed Web of Science ®Google Scholar
• Rubio ML, Martin-Mosquero MC, Ortega M, Peces-Barba G, González-Mangado N. Oral N-acetylcysteine attenuates elastase-induced pulmonary emphysema in rats. Chest 2004; 125(4):1500–1506.
   PubMed Web of Science ®Google Scholar
• Urban T, Akerlund B, Jarstrand C, Lindeke B. Neutrophil function and glutathione-peroxidase (GSH-px) activity in healthy individuals after treatment with N-acetyl-L-cysteine. Biomed Pharmacother 1997; 51(9):388–390.
   PubMed Web of Science ®Google Scholar
• Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration 2000; 67(5):552–558.
   PubMed Web of Science ®Google Scholar
• Mata M, Morcillo E, Gimeno C, Cortijo J. N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV). Biochem Pharmacol 2011; 82(5):548–555.
   PubMed Web of Science ®Google Scholar
• Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005; 60(4):293–300.
   PubMed Web of Science ®Google Scholar
• Decramer M, Rutten-van Molken M, Dekhuijzen PNR, Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet 2005; 365:1552–1560.
   PubMed Web of Science ®Google Scholar
• Dekhuijzen PNR. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004; 23:629–636.
   PubMed Web of Science ®Google Scholar
• National Clinical Guideline Centre. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. London: National Clinical Guideline Centre. Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/English, 2010.
   Google Scholar
• Gerrits CMJM, Herings RMC, Laufkens HGM, N-Acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21:795–798.
   PubMed Web of Science ®Google Scholar
• Zuin R, Palamidese A, Negrin R, High dose N-Acetylcysteine in Patients with Exacerbations of Chronic Obstructive Pulmonary Diseases. Clin Drug Invest 2005; 25(6):401–408.
   PubMed Web of Science ®Google Scholar
• Moher D, Schulz KF, Altman DG, The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357:1191–1194.
   PubMed Web of Science ®Google Scholar
• Declaration of Helsinki World Medical Association. Available from: http://www.wma.net/e/ethicsunit/helsinki.htm.
   Google Scholar
• International Conference on Harmonisation (ICH)—Good Clinical Practice (GCP). ICH GCP (E6): Adopted by CPMP, July 1996, issued as CPMP/ICH/135/95/Step5, Explanatory Note and Comments to the above, issued as CPMP/768/97.
   Google Scholar
• Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA, Manitoba W. Antibiotic therapy in exacerbation of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196–204.
   PubMed Web of Science ®Google Scholar
• Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56:880–887.
   PubMed Web of Science ®Google Scholar
• Crapo RO, Hankinson JL, Irvin C, American Thoracic Society. Standardization of spirometry—1994 update. Am J Respir Crit Care Med 1995; 152: 1107–1136.
   PubMed Web of Science ®Google Scholar
• Quanjer PH. Standardized lung function testing. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:5–40.
   PubMedGoogle Scholar
• Zheng JP, Zhong NS. Normative values for pulmonary function testing in Chinese adults. Chin Med J 2002; 115:50–54.
   PubMed Web of Science ®Google Scholar
• Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, Make BJ, Rabe KF, Rennard SI, Sciurba FC, Silverman EK, Vestbo J, Washko GR, Wouters EF, Martinez FJ. Chronic obstructive pulmonary disease phenotypes: the future of COPD.Am J Respir Crit Care Med 2010; 182(5):598–604.
   PubMed Web of Science ®Google Scholar
• Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslem TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297–1303.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M, for the UPLIFT Study Investigators. A 4-year trial of tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359:1543–1554
   PubMed Web of Science ®Google Scholar
• Zheng JP, Zhong NS, Jiang M, Carbocisteine for acute exacerbations of COPD — Authors’ reply. Lancet 2008; 372:1631–1632.
   Web of Science ®Google Scholar
• Vestbo J, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). ERJ 2008; 31:869–873.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128–1138.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhou Y, Wang X, Wang D, Zheng J, Zhong N, Ran P, Biomass fuels are the probable risk factor for chronic obstructive pulmonary disease in rural South China. Thorax 2007; 62:889–897.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008; 31: 742–750.
   PubMed Web of Science ®Google Scholar
• Zhang F-Q, Zheng J-P, Wang J-H, Lu W-B, Wu R-X, Li X-S, Xian Q-Z, Gao H, Jiang M. Comparison of lung volume response with airflow response to bronchodilator in patients with chronic obstructive pulmonary disease. Zhong Hua Jie He Hu Xi Za Zhi (Chin J Tuberc Respir Dis) 2010; 33(2):109–113.
   PubMedGoogle Scholar